CYTOXAN PWS FOR INJ 2000MG/VIAL 2000 MG — DIN 00602949
CYCLOPHOSPHAMIDE : 2000 MG · BRISTOL-MYERS SQUIBB CANADA · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is CYTOXAN PWS FOR INJ 2000MG/VIAL?
CYTOXAN PWS FOR INJ 2000MG/VIAL 2000 MG contains CYCLOPHOSPHAMIDE : 2000 MG. It is listed in the Health Canada Drug Product Database under DIN 00602949, held by BRISTOL-MYERS SQUIBB CANADA, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 17-Oct-2008. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CYTOXAN PWS FOR INJ 2000MG/VIAL used for?
Malignant lymphomas (Hodgkin's, lymphocytic, etc.), multiple myeloma, leukemias (CLL, CGL, AML, ALL), mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, breast/lung cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cyclophosphamide cost around the world?
Cyclophosphamide is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 5 | 9 | AUD███.██ |
| Saudi Arabia | public | 7 | 7 | SAR███.██ |
| Morocco | PPV (public price) | 6 | 6 | MAD███.██ |
| United States | acquisition | 2 | 6 | USD███.██ |
| South Africa | single exit price | 2 | 6 | ZAR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
38 pack listings across 26 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Cyclophosphamide pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Cyclophosphamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Cyclophosphamide, across 28 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 6 | 6 | PROCYTOX, PROCYTOX TAB 25MG, PROCYTOX TAB 50MG | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 3 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| STERIMAX INC | 3 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| ANDONE PHARMACEUTICAL INC | 2 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| CARTER-HORNER CORP. | 6 | 0 | PROCYTOX FOR INJECTION 2000MG PWS IV, PROCYTOX PWS 500MG, PROCYTOX TAB 25MG, PROCYTOX TABLETS 50MG, PROCYTOX VIAL 1000MG, +1 more | No marketed DIN |
| BRISTOL-MYERS SQUIBB CANADA | 4 | 0 | CYTOXAN PWS FOR INJ 1000MG/VIAL, CYTOXAN PWS FOR INJ 2000MG/VIAL, CYTOXAN TAB 25MG, CYTOXAN TAB 50MG | No marketed DIN |
| ACCORD HEALTHCARE INC | 3 | 0 | CYCLOPHOSPHAMIDE FOR INJECTION | No marketed DIN |
| DR REDDY'S LABORATORIES LTD | 1 | 0 | CYCLOPHOSPHAMIDE FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2000 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Vials: 100, 750, 1000, 2000 mg. Tablets: 25 mg (bottle of 100), 50 mg (bottles of 100 or 1000). |
| Storage | Store vials and tablets at temperatures not exceeding 25°C. Do not use vials if signs of melting (clear/yellowish viscous liquid) are present. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Cyclophosphamide |
|---|---|
| ATC code | L01AA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00602949 |
|---|---|
| DIN (unpadded, as printed on some documents) | 602949 |
| Brand name | CYTOXAN PWS FOR INJ 2000MG/VIAL |
| Generic / active ingredient | CYCLOPHOSPHAMIDE : 2000 MG |
| Market authorization holder | BRISTOL-MYERS SQUIBB CANADA |
| Health Canada schedule | Prescription |
| ATC code | L01AA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01AA |
| Current status | CANCELLED POST MARKET |
| Status date | 17-Oct-2008 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Induction: 40-50 mg/kg IV (initial loading) or 1-5 mg/kg/day orally. Maintenance: 1-5 mg/kg orally daily, 10-15 mg/kg IV every 7-10 days, or 3-5 mg/kg IV twice weekly. Adjust for bone marrow compromise.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Sensitivity to cyclophosphamide; severe leukopenia; thrombocytopenia; hepatic or renal dysfunction.
Warnings and precautions
Potent drug; use only by experienced physicians. Risk of hemorrhagic cystitis, secondary malignancies, impaired wound healing, and serious infections (e.g., Varicella-Zoster).
Is Cyclophosphamide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by ANDONE PHARMACEUTICAL INC (Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTION USP" aria-label="Anticipated Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTI), last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 28 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02547694 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | 02546744 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02560216 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02560224 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | Injection | STERIMAX INC | MARKETED | 02547686 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | 02546736 |
| PROCYTOX | 200 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241797 |
| PROCYTOX | 1000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241799 |
| PROCYTOX | 2000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241800 |
| PROCYTOX | 500 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241798 |
2 · Same class — other molecules in ATC L01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION · CYCLOPHOSPHAMIDE FOR INJECTION USP · CYTOXAN PWS FOR INJ 1000MG/VIAL · CYTOXAN PWS FOR INJ 2000MG/VIAL · +10 more | 28 | 12 | Yes |
| Bendamustine | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION · BENVYON · ESAMUZE · NAT-BENDAMUSTINE · +1 more | 18 | 11 | Yes |
| Melphalan | ALKERAN · MELPHALAN FOR INJECTION · TARO-MELPHALAN | 8 | 4 | Yes |
| Ifosfamide | IFEX · IFEX PWS 1GM/VIAL · IFEX PWS 2G/VIAL · IFEX PWS 3GM/VIAL · +1 more | 7 | 2 | Yes |
| Chlormethine | LEDAGA · MUSTARGEN | 2 | 1 | Yes |
| Chlorambucil | LEUKERAN | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01AX | Dacarbazine · Temozolomide | 42 | 26 |
| L01AC | Thiotepa | 9 | 6 |
| L01AB | Busulfan · Treosulfan | 10 | 4 |
| L01AD | Carmustine · Lomustine · Streptozocin | 8 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CYTOXAN PWS FOR INJ 2000MG/VIAL called?
The same molecule, Cyclophosphamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Endoxan | Latin | Australia, South Africa |
| Cyclophosphamide (NorthStar, USA) | Latin | Australia |
| Cyclophosphamide (Sagent, USA) | Latin | Australia |
| CYCLOPHOSPHAMIDE-REACH | Latin | Australia |
| Cyclonex | Latin | Australia |
| ENDOXAN SUGAR COATED TABLET | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.